CA2466170C - Hexa-, hepta-, and octapeptides having antiangiogenic activity - Google Patents

Hexa-, hepta-, and octapeptides having antiangiogenic activity Download PDF

Info

Publication number
CA2466170C
CA2466170C CA2466170A CA2466170A CA2466170C CA 2466170 C CA2466170 C CA 2466170C CA 2466170 A CA2466170 A CA 2466170A CA 2466170 A CA2466170 A CA 2466170A CA 2466170 C CA2466170 C CA 2466170C
Authority
CA
Canada
Prior art keywords
fmoc
ile
arg
minutes
thr
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
CA2466170A
Other languages
English (en)
French (fr)
Other versions
CA2466170A1 (en
Inventor
Fortuna Haviv
Michael F. Bradley
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
AbbVie Inc
Original Assignee
Abbott Laboratories
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US10/000,681 external-priority patent/US20030125259A1/en
Application filed by Abbott Laboratories filed Critical Abbott Laboratories
Publication of CA2466170A1 publication Critical patent/CA2466170A1/en
Application granted granted Critical
Publication of CA2466170C publication Critical patent/CA2466170C/en
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/08—Peptides having 5 to 11 amino acids
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/06—Linear peptides containing only normal peptide links having 5 to 11 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/18—Feminine contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/14—Vasoprotectives; Antihaemorrhoidals; Drugs for varicose therapy; Capillary stabilisers

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Diabetes (AREA)
  • Immunology (AREA)
  • Oncology (AREA)
  • Dermatology (AREA)
  • Cardiology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Hematology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Epidemiology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Vascular Medicine (AREA)
  • Endocrinology (AREA)
  • Rheumatology (AREA)
  • Obesity (AREA)
  • Urology & Nephrology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Pain & Pain Management (AREA)
  • Communicable Diseases (AREA)
  • Gynecology & Obstetrics (AREA)
  • Reproductive Health (AREA)
  • Orthopedic Medicine & Surgery (AREA)
CA2466170A 2001-10-31 2002-10-30 Hexa-, hepta-, and octapeptides having antiangiogenic activity Expired - Fee Related CA2466170C (en)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US10/000,681 US20030125259A1 (en) 2001-10-31 2001-10-31 Octa- and nonapeptides having antiangiogenic activity
US10/000,681 2001-10-31
US10/263,812 US20030096758A1 (en) 2001-10-31 2002-10-04 HEPTA-, OCTA- and nonapeptides having antiangiogenic activity
US10/263,812 2002-10-04
PCT/US2002/034811 WO2003037268A2 (en) 2001-10-31 2002-10-30 Hepta-, octa- and nonapeptides having antiangiogenic activity

Publications (2)

Publication Number Publication Date
CA2466170A1 CA2466170A1 (en) 2003-05-08
CA2466170C true CA2466170C (en) 2011-04-05

Family

ID=26667985

Family Applications (1)

Application Number Title Priority Date Filing Date
CA2466170A Expired - Fee Related CA2466170C (en) 2001-10-31 2002-10-30 Hexa-, hepta-, and octapeptides having antiangiogenic activity

Country Status (11)

Country Link
EP (1) EP1451210A4 (pl)
JP (1) JP4362064B2 (pl)
CN (1) CN1639188A (pl)
BR (1) BR0209758A (pl)
CA (1) CA2466170C (pl)
IL (1) IL161527A0 (pl)
MX (1) MXPA04004131A (pl)
NZ (1) NZ532367A (pl)
PL (1) PL374238A1 (pl)
TW (1) TWI268934B (pl)
WO (1) WO2003037268A2 (pl)

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5932545A (en) * 1997-03-17 1999-08-03 Abbott Laboratories Antiangiogenic drug to treat cancer, arthritis and retinopathy
AU759144B2 (en) * 1998-05-05 2003-04-03 Adherex Technologies Inc. Compounds and methods for modulating nonclassical cadherin-mediated functions
AU764277B2 (en) * 1998-05-22 2003-08-14 Abbvie Inc. Peptide antiangiogenic drugs

Also Published As

Publication number Publication date
CA2466170A1 (en) 2003-05-08
WO2003037268A2 (en) 2003-05-08
BR0209758A (pt) 2005-10-04
CN1639188A (zh) 2005-07-13
IL161527A0 (en) 2004-09-27
EP1451210A4 (en) 2009-05-27
EP1451210A2 (en) 2004-09-01
PL374238A1 (pl) 2005-10-03
MXPA04004131A (es) 2004-07-08
TW200302832A (en) 2003-08-16
TWI268934B (en) 2006-12-21
NZ532367A (en) 2006-01-27
JP4362064B2 (ja) 2009-11-11
WO2003037268A3 (en) 2003-09-12
JP2005512981A (ja) 2005-05-12

Similar Documents

Publication Publication Date Title
US20030125260A1 (en) Tetra-and pentapeptides having antiangiogenic activity
US20050215484A1 (en) Di-, tri-, and tetra-peptides having antiangiogenic activity
EP1232183B1 (en) Peptides having antiangiogenic activity
CA2386893A1 (en) N-alkylated peptides having antiangiogenic activity
US20030050246A1 (en) Peptides having antiangiogenic activity
US20060194737A1 (en) Hepta-, octa-and nonapeptides having antiangiogenic activity
CA2466170C (en) Hexa-, hepta-, and octapeptides having antiangiogenic activity
US6777535B1 (en) N-alkylated peptides having antiangiogenic activity
US6753408B1 (en) Peptides having antiangiogenic activity
US7037897B2 (en) TRI-, TETRA-, and penta-peptides having antiangiogenic activity
US7169888B2 (en) Tetra-, penta-, hexa- and heptapeptides having antiangiogenic activity
US7122625B2 (en) Hexa-, hepta-, and octapeptides having antiangiogenic activity
EP2177530B1 (en) Octapeptide having antiangiogenic activity
US20030105022A1 (en) Tetra-, penta-, hexa- and heptapeptides having antiangiogenic activity
US20030105025A1 (en) Tri-and tetrapeptides having antiangiogenic activity
CA2466152A1 (en) Tetra-, penta-, hexa- and heptapeptides having antiangiogenic activity
US20030119746A1 (en) Hepta-and octapeptides having antiangiogenic activity
US20030119745A1 (en) HEXA- and heptapeptides having antiangiogenic activity
US20030125261A1 (en) Penta- and hexapeptides having antiangiogenic activity
AU2002353929A1 (en) Hepta-, octa- and nonapeptides having antiangiogenic activity

Legal Events

Date Code Title Description
EEER Examination request
MKLA Lapsed

Effective date: 20151030